Gilead signs a US$4.9 billion acquisition deal with Forty Seven
By Nikita Chaurasia  Date: 2020-03-03

Gilead signs a US$4.9 billion acquisition deal with Forty Seven

The deal would improve Gilead’s portfolio in Oncology and would allow the firm to conduct new First-in-Class oncology programs.

Gilead Sciences Inc., a U.S. based biotechnology company, has recently announced that it has inked a definitive agreement to acquire immuno-oncology company, Forty Seven Inc. for $4.9 billion. Reportedly, the transaction valued each share at $95.50 and was unanimously approved by the Boards of Directors of both the companies.

Reports cite that this acquisition deal could close by Q2 of 2020, subject to customary closing conditions and regulatory approvals. With this acquisition, Gilead’s immuno-oncology R&D portfolio would greatly benefit from the addition of Forty Seven’s lead drug candidate, magrolimab. 

Speaking on the move, Daniel O’Day, Chief Executive Officer and Chairman, Gilead Sciences, said that this deal would enhance Gilead’s presence in immuno-oncology and strengthen its portfolio as well as its clinical pipeline. Moreover, magrolimab would benefit its work in hematology, adding up a non-cell therapy initiative that accompanies Kite’s lineup of cell therapies developed for hematological cancers. 

Additionally, the biotech is looking forward to working with Forty Seven’s highly experienced team as it develops new treatments for some of the most complicated cancer forms, adds O’Day

Prior to this news, Gilead Sciences had made headlines when it revealed that it has appointed Sandra Horning, MD, in its Board of Directors. Reportedly, Dr. Horning had previously served as the Global Head of Product Development and Chief Medical Officer for Roche. 

Commenting on which, O’Day said that the company is delighted to welcome Sandra Horning in its Board of Directors and is looking forward to sharing her immense experience and vast industry expertise in drug development across numerous therapeutic sectors.

Additionally, Dr. Horning possesses the perspective of a leading physician who has invested over two decades in cancer treatment, that would come in handy while making strategic decisions for the company.

Source Credit: https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Ikea buys Geomagical Labs to enhance AI-based visualization for users
Ikea buys Geomagical Labs to enhance AI-based visualization for users
By Nikita Chaurasia

Ikea, the leading home décor and furnishing giant, has recently acquired Geomagical Labs, which is a startup developing artificial intelligence-based imaging. Geomagical Labs has been developing various technologies based on computer vision t...

Insight unveils new Tech Journal for small & midmarket businesses
Insight unveils new Tech Journal for small & midmarket businesses
By Nikita Chaurasia

Insight Enterprises, a renowned US-based technology company and an integrator of the Insight Intelligent Technology SolutionsTM for companies of all sizes, reportedly unveiled a new magazine titled Tech Journal. This magazine would be published each...

Tesla CEO Elon Musk reveals plans to build ventilators for COVID-19
Tesla CEO Elon Musk reveals plans to build ventilators for COVID-19
By Nikita Chaurasia

U.S. auto giant Tesla, Inc.’s CEO, Elon Musk has recently made headlines when he announced that his company is planning to develop ventilators for COVID-19 patients. The move comes after the United States government’s latest appeal for do...

Google News launches Project Oasis to support local entrepreneurs
Google News launches Project Oasis to support local entrepreneurs
By Nikita Chaurasia

Google News has apparently launched Project Oasis in partnership with the University of North Carolina, Table Stakes co-founder Doug Smith, and LION Publishers. The partnership is aimed at helping the founders and aspiring founders of digital ne...

Pfizer collaborates with BioNTech to develop coronavirus vaccine
Pfizer collaborates with BioNTech to develop coronavirus vaccine
By Nikita Chaurasia

Increasing numbers of coronavirus cases worldwide have prompted researchers to develop a potential vaccine candidate to treat COVID-19 patients. Pfizer Inc., one of the leading American pharmaceutical companies, has reportedly collaborated with BioNT...